Track market-moving stories before they get noisy

There's no shortage of naysayers when it comes to Nvidia (NVDA -2.01%). Just 1.18% of its outstanding shares are currently being shorted, but think about what that means for a company with a market cap just above $5.5 trillion.

There are nearly $57 billion in short positions out there, and that doesn't include put options, bearish ETFs, or other derivative activity. The actual number of shares sold short has actually increased 40% over the past year, and the value of those bearish wagers has risen another 35% on top of that.

The bears are everywhere, but I see that as more of an opportunity than a threat. Let's go over some of the knocks on Nvidia. I want to counter by pointing out what the worrywarts might be missing.

Image source: Getty Images.

1. Nvidia is priced for perfection There is nothing that I love more than when a bear argues that a stock is "priced for perfection." The assumption is that current expectations are too high and that the stock is bumping up against the ceiling, with so much air below it on the way down to the floor.

Last month's fiscal second quarter was a perfect example of Nvidia stock perpetually scaling the wall of worry. Bears were banking on analysts aiming too high by targeting 97% in top-line growth. It would be the fourth consecutive quarter of accelerating year-over-year growth.

How is that possible with a company as large as Nvidia? Expectations were high. Reality was kinder. Here's a look at the company's top-line growth:

Q2 FY 2026: 56% Q3 FY 2026: 63% Q4 FY 2026: 73% Q1 FY 2027: 85% Q2 FY 2027: 106% The late-August financial update gets even better. Those same analysts tagged by bears as overly ambitious are serial lowballers. They projected revenue would decelerate sharply to just 45% for fiscal year 2028, which starts in February. Nvidia shattered those crystal balls two weeks ago by forecasting 70% growth for next year.

Perfection isn't the ceiling. Market winners thrive in the debunking process.

Premium Feature

Moneyball Superscore

94/100

Today's Change

(

-2.01

%) $

-4.63

Current Price

$

225.73

2. Rivals will gain market share at Nvidia's expense It would be naive for a bull like me to assume that Nvidia will be the king of the hill forever. Competitive advantages can weaken over time, just as they have been strengthening for years. A disruptor can pioneer a better mousetrap for the AI revolution or whatever giant tech trend comes next.

The one thing that's fair to say is that it's not happening now. Let's have Advanced Micro Devices (AMD +5.90%) enter the chat. AMD has a colorful history of needling the market leader, and it's certainly cashing in on the AI boom Nvidia is championing.

AMD stock has outperformed Nvidia over the past year by more than tripling. However, in its latest quarter -- and I'll point out that their fiscal quarters ended about a month apart -- AMD's overall revenue rose just 50%, half of Nvidia's top-line growth.

I'll beat the bears to what they're thinking. Zoom in on AMD's data center business, which now accounts for more than half (58%) of its revenue, and that business skyrocketed 107% for the quarter. That's awesome, but Nvidia's data center revenue, which accounts for 93% of its results, soared 117%.

In the end, AMD's data center business delivered $3.5 billion in incremental revenue compared to a year earlier. Nvidia tacked on $48 billion in incremental data center revenue.

3. Margins will inevitably contract Let's close on a margin of error. Nvidia's gross margin was 75% in its latest quarter. The adjusted net margin was a jaw-dropping 56%. It's easy to question the sustainability of those levels. Unlike the flawed "priced for perfection" argument, there is a clear ceiling here: Gross margin will never exceed 100%, and the after-tax adjusted bottom line will naturally be well below that.

The reasonable bear case is that growth may continue but decelerate. Margins will contract, so earnings will grow even slower than the slowing top line -- if not eventually turn into negative year-over-year earnings growth.

Set aside that high bandwidth memory (HBM) makers riding Nvidia's coattails are currently generating gross margins approaching 85%. With competition percolating, Nvidia will need to keep innovating and fortifying its moat. It probably has more pricing flexibility now than the bears think. With third-party HBM becoming a larger cost component in the AI build-out, won't it make it even riskier for a company to bank on non-Nvidia AI chips and accelerators?

In the meantime, you can buy the stock for less than 15 times next year's projected earnings. This is why the bears aren't arguing that Nvidia is too expensive, as it's trading at a discount to the overall market despite growing substantially faster. Nvidia will be volatile, but it's built to win.

Ivan Feinseth believes Nvidia (NVDA) purchasing Hugging Face for just under $13 billion is something that accelerates the Mag 7 giant's software momentum. He says Hugging Face will add efficiency and expand the runway for future prospects.

Nvidia (NVDA -2.01%) has delivered plenty of organic growth over its history, but acquisitions have also played a major role in its expansion from a GPU designer to a comprehensive AI platform, or factory, as CEO Jensen Huang calls it.

For example, it acquired the data center networking specialist Mellanox for $6.9 billion in 2019, and it now anchors a business that generates more than $31 billion in revenue annually.

The Hugging Face acquisition, which it announced last week, will be its biggest ever at a purchase price of $12.9 billion. Nvidia did spend $20 billion in a deal with Groq, but that was a non-exclusive technology licensing and talent agreement, rather than an outright acquisition.

Acquisitions have been hit-or-miss in the tech sector, and $12.9 billion is a large sum even by modern standards. Let's take a look at what Nvidia gets for that money, before discussing what the deal means for investors.

Image source: Nvidia.

What Hugging Face brings to NvidiaHugging Face is an online platform for building AI and machine learning tools, and is sometimes described as "GitHub for machine learning," referring to the code repository now owned by Microsoft.

Given its position at the top of the funnel in the AI stack, you can see how the platform would be valuable to Nvidia, whose future depends on its ability to continue to dominate the AI chip ecosystem.

Hugging Face has a base of 18 million developers, researchers, and creators on the platform, and more than 3 million models, 500,000 data sets, and 1 million applications. It's currently used by more than 200,000 companies for AI development.

Hugging Face will remain an open platform, and Nvidia has been committed to open models for years. The acquisition seems to be more about gaining a valuable top-of-the-funnel platform than integrating Hugging Face's infrastructure into Nvidia, though Nvidia is the largest contributor of open models and data to Hugging Face. Still, Nvidia's ownership of Hugging Face should increase its influence over the software layer that gets built on its hardware. Open-source model adoption also drives demand for Nvidia's hardware, so supporting Hugging Face can help grow the platform and increase demand for its chips and hardware.

Plenty of tech acquisitions have blown up in the past. Microsoft, for example, has a long history of botched acquisitions, including Nokia’s handset business, Skype, the videoconferencing platform, and aQuantive, a digital marketing company.

Nvidia, on the other hand, has a more successful acquisition history, and it's stuck to its strengths in semiconductors, rather than chasing every emerging business as tech giants like Microsoft sometimes have.

However, there's a simpler reason why the Hugging Face acquisition shouldn't faze investors. While the $12.9 billion is nominally a lot of money, for a company like Nvidia, it's actually quite affordable. Based on Nvidia's net income of $59.7 billion in the second quarter, Hugging Face costs it roughly three weeks of profits, and its profits are growing rapidly.

Companies can spend their profits on a few different things. Generally, the available options are capital expenditures to invest in growth, acquisitions, investments, debt repurchases, dividends, or share buybacks.

At this point, Nvidia seems to be growing too quickly, and the stock is too expensive for the company to be spending a substantial percentage of its profits on returning capital to shareholders through dividends or buybacks.

I'd rather the company use that money to invest in its growth and widen its economic moat in AI chips, and it seems to be doing that. In addition to the Hugging Face acquisition, it's built a broad network of investments and partnerships with AI labs, neocloud companies, other chipmakers, and partners like Space Exploration Technologies. Its portfolio of publicly traded companies was worth $63.4 billion at the end of Q2, and that doesn't include investments in companies like OpenAI and Anthropic.

Investors should hope to see more such acquisitions like Hugging Face as the company has more than enough capital to spend on them, and doing so will help further entrench and expand its AI empire.

Nvidia (NVDA -2.01%) has been a key company -- and some may say the key company -- driving the artificial intelligence (AI) revolution. This is because the tech giant designs the most powerful graphics processing units (GPUs), the chips fueling AI, and has expanded this expertise into the creation of complete systems. Today, Nvidia is a full-stack AI company, offering customers a vast selection of products and services needed along the AI path.

All of this has translated into explosive growth and record levels of earnings. In the most recent quarter, Nvidia's revenue soared 106% to $96 billion. And profit followed, advancing 126% to $59 billion. Nvidia is benefiting from massive investments in AI infrastructure; capital expenditures by the company's top five customers are forecast to reach $1.3 trillion next year.

Nvidia shared this and other news just last month during its fiscal 2027 second-quarter earnings report. Now, Sept. 10 represents a fresh opportunity to hear more from this AI powerhouse. My prediction is that it will be a big day for shareholders. Here's what to watch.

Image source: Getty Images.

Nvidia's soaring earningsSo, first, a quick summary of Nvidia's recent and long-term performance. The company's earnings and stock price have soared over the past few years, as shown in the chart below, driven by its dominance in the AI chip market.

NVDA data by YCharts

Nvidia entered this market about a decade ago, well before the AI boom started, and designed its GPUs specifically to serve AI. In the past, Nvidia focused its designs on the gaming space -- this remains a market for Nvidia, but the AI opportunity has become the tech giant's biggest business. For example, in the recent quarter, data center revenue came in at $89 billion on the total $96 billion in revenue.

Nvidia's stock price continues to climb, but with a gain of about 20% so far this year, it's underperforming certain AI peers such as chip rivals Advanced Micro Devices and Intel, and memory chip giant Micron Technology. Those three players have seen their stock prices soar in the triple digits. This is as investors shift into other AI players that didn't climb as much as Nvidia in the earlier stages of the AI boom.

Premium Feature

Moneyball Superscore

94/100

Today's Change

(

-2.01

%) $

-4.63

Current Price

$

225.73

An update from NvidiaNow, let's consider what's set to happen on Sept. 10. Nvidia is set to make a presentation at the Goldman Sachs Communacopia + Technology Conference at 8:50 a.m. Pacific Time, and this will be an opportunity for investors to hear the latest news at a crucial moment in time: as Nvidia rolls out its latest update, the Vera Rubin platform. The company said last month that it had begun production shipments of Rubin and that the system would likely account for 20% of data center revenue in the third quarter.

This launch also marks Nvidia's entry into the stand-alone central processing unit (CPU) market, one that so far has been dominated by AMD and Intel. Nvidia has set its sights on leadership here, so any CPU forecasts will be points to watch.

For the first time, Nvidia recently offered an annual growth forecast, predicting 70% year-over-year revenue growth for the 2028 fiscal year -- that's the fiscal year that begins in early 2027. Investors should look for additional comments, potentially concerning supply constraints and demand, that may offer further clues about what to expect.

Nvidia's headwindsMeanwhile, tight memory supply and higher prices have been and continue to be a headwind for Nvidia. The company might offer investors additional details about how it's handling this challenge. And while we're on the subject of headwinds, it will also be important to listen for any comments on potential sales in China. Restrictions by the U.S. blocked Nvidia's chip sales to China in April 2025, and though the U.S. has given the company the go-ahead, Nvidia still hasn't been able to reenter this high-potential market.

If Nvidia addresses some of these points, my prediction is that Sept. 10 could be a big day for shareholders, and the stock could take off in the days to follow. But even if I'm wrong and Nvidia shares don't react after the Goldman Sachs conference, that's OK. The company, thanks to its solid AI empire, is still well-positioned to deliver a win to investors over the long run.

Nvidia's (NVDA -2.01%) accomplishments speak for themselves, but despite the stock having grown to a market cap of more than $5 trillion and it becoming the most profitable company in the world, there's still a lot of skepticism facing it.

Even as revenue nearly doubled in its most recent quarter, the stock trades at a price-to-earnings ratio of just 29, roughly in line with the S&P 500, indicating that investors expect its long-term earnings growth to generally resemble the broad-market index, even though it more than doubled net income in its latest quarter and expects strong growth to continue at least through 2027.

There are a number of reasons why Nvidia doesn't get the premium you might expect for a company growing this fast. First, the semiconductor industry is historically cyclical, and investors are expecting the momentum in the AI boom to eventually fade. At that point, Nvidia's revenue and earnings growth could turn negative as it has in past cycles. Second, competitors, including Nvidia's hyperscaler customers, are building their own chips to substitute for Nvidia components. While they're unlikely to replace them entirely, it could signal that Nvidia's competitive advantage is likely to erode over time. Finally, some investors think that depreciation in Nvidia's chips is an outsize risk facing the company and the broader AI boom. If its chips lose their value quickly, that is likely to hurt their selling price and the broader sustainability of AI, as eventually, Nvidia's customers will need to sell enough services to pay for its chips.

This theory, advanced by Michael Burry of "The Big Short" fame, has been used to criticize hyperscalers and neocloud companies, as well as Nvidia.

However, there's some evidence that Nvidia chips are retaining their value much better than the skeptics would expect.

Image source: Nvidia.

Jensen Huang weighs inThe comments and chart below, taken from X, show the market average for live cloud GPU rental costs based on the Ornn H100 SXM Index.

NVIDIA compute is fungible, durable and highly rentable. It is a productive, revenue-generating asset. https://t.co/cvmjaNoiK8

— Jensen Huang (@JensenHuang) September 8, 2026 The H100 is a three-year-old training chip. Its rental price is up 22 percent on the month, to $3.28 an hour.

Every depreciation schedule assumes a chip this old only loses value. The market is paying up for it instead. pic.twitter.com/TNSqgys3vx

— Ornn (@OrnnExchange) September 7, 2026

Image source: Ornn. Via X.

As you can see, rental prices per hour for an H100 GPU, which were first launched nearly four years ago, are up 22% over the last month, even as Nvidia is now launching the new Rubin platform. the Rubin GPU, or R100, will make the H100 two generations old.

Rental and purchase prices for the H100 have indeed come down substantially from their peak in 2023, when generative AI was just starting to take off, but it's noteworthy that they were still able to increase their value at this point, even as newer options on the market emerge. The R100 will have several times as much memory as the H100 and use a superior, updated architecture.

Even the A100, the generation before the H100, remains in high demand, as some customers prefer the cheaper per-hour rental costs of the A100. Rather than disrupting itself with newer chips, Nvidia seems to be benefiting from a multi-tiered pricing model in which premium customers can pay premium prices for the newest chips and budget customers can pay lower prices for older chips.

Premium Feature

Moneyball Superscore

94/100

Today's Change

(

-2.01

%) $

-4.63

Current Price

$

225.73

What it means for NvidiaThe durability of H100 pricing offers yet another reason to be skeptical of the bearish thesis on the stock and to bet on the company's continued leadership in AI chips.

It's a reminder also that Nvidia, if anything, has been underestimated by Wall Street over the last few years, as the analyst consensus has been woefully short. Similarly, bearish predictions for the stock have fallen flat. Given the fact that the business just doubled in size in the most recent quarter, prices for chips that are now two generations old are holding up, and the stock is trading on par with the S&P 500, Nvidia continues to look like an excellent buy.

powered by

NVDA into Sep 10

Buy NASDAQ:NVDA. The stock is near highs but still “cheap” versus compute peers on 2028 earnings, and Sep 10 is a clear catalyst: Huang’s Goldman fireside chat can push AI demand and next-hardware confidence higher, keeping the market willing to pay up for accelerating earnings. This is a momentum + valuation support setup.

Key Risk: Huang fails to lift growth expectations (enterprise adoption and next-platform demand sound flat), so the “cheap” multiple compresses fast.

Hugging Face deal as a hedge

Buy NASDAQ:NVDA with a focus on the $12.93B Hugging Face angle. If Huang reinforces that Nvidia can broaden beyond hyperscalers via open-weight models and enterprise distribution, the market will price in a more durable revenue stream and less customer concentration risk—secondarily supporting NVDA’s long-term margins and stickiness.

Key Risk: The Hugging Face strategy doesn’t translate into measurable enterprise traction (or the deal faces regulatory/implementation delays), so concentration risk stays unresolved.

Nvidia stock NASDAQ:NVDA is sitting less than 5% below its record high, but the next catalyst arrives on September 10.

Chief executive Jensen Huang will participate in a fireside chat at Goldman Sachs’ Communacopia + Technology Conference at 8:50 a.m. PT, where investors will listen for signals on AI demand, enterprise adoption and Nvidia’s next hardware.

Nvidia closed at $225.73 on Tuesday, down 2.01%, leaving the stock about 4.6% below its $236.54 all-time high.

Nvidia’s shares are close to a record after another AI-driven rally, yet some analysts argue earnings expectations are rising even faster than the stock.

Cantor Fitzgerald analyst C.J. Muse reiterated an Overweight rating and a $350 price target on September 8. Muse said Nvidia trades at the “cheapest” valuation among compute names based on calendar-2028 earnings estimates.

Cantor also argued that Nvidia remains under-owned by hedge funds and long-only managers.

That makes Huang’s appearance more important.

If he reinforces expectations for accelerating revenue or a widening customer base, investors may continue to view Nvidia as inexpensive relative to future earnings.

But that support depends on estimates continuing to rise. If growth expectations flatten, the stock becomes harder to defend.

Nvidia’s next leg depends on proving AI demand is expanding beyond a small group of hyperscalers.

Recent results from Dell strengthened that argument. Dell raised its annual outlook after reporting record revenue and a large AI-server backlog.

D.A. Davidson analyst Gil Luria told MarketWatch that Dell’s results were another sign the enterprise AI-compute market has momentum “beyond the current hyperscaler market.”

They will listen for commentary on enterprise adoption, sovereign AI, supply constraints and Feynman, Nvidia’s next architecture.

A broader customer base would make Nvidia’s growth story more durable.

If AI spending remains concentrated among Microsoft, Amazon, Meta and other technology giants, investors will keep worrying about concentration.

Customer concentration remains the uncomfortable riskThe bullish case has a major weakness, as Nvidia’s latest regulatory filing showed that three direct customers represented 16%, 15% and 13% of total revenue in the first half of fiscal 2027.

Investor Dan Niles highlighted the same issue this week, noting that Nvidia’s largest customers are increasingly designing their own application-specific chips.

That creates an unusual tension: the companies funding Nvidia’s growth also have the strongest incentives to reduce their dependence on its GPUs.

Nvidia’s planned $12.93 billion acquisition of Hugging Face could help address that risk by giving the company access to more than 18 million developers and a stronger route into enterprise AI.

Niles said that open-weight models could eventually dominate LLM usage, allowing Nvidia to sell a broader stack directly to enterprises rather than relying heavily on hyperscalers.

AT&T on Tuesday said it would work with Amazon to deliver satellite internet to business customers as the telecommunications industry looks to keep SpaceX on its toes.

Tomorrow, AT&T's Chairman and Chief Executive Officer will participate in a fireside chat at 4:05 p.m. ET to discuss the Company's progress on its multi-year growth strategy Key Takeaways: AT&T's structural advantage from years of industry-leading fiber and 5G investments positions the Company to lead the next era of connectivity AT&T reiterates the financial outlook and capital allocation plan provided with its second-quarter 2026 earnings release DALLAS, Sept.

Netflix Inc (NASDAQ:NFLX) stock traded lower by more than 2% on Tuesday as risk appetite softens across growth and media names.

The Nasdaq is down 0.20% while the S&P 500 has shed 0.44%, and Communication Services is also in the red (down 0.67%), keeping pressure on the group.

• Netflix stock is trending lower. What’s driving NFLX stock lower?

The U.S. streaming giant faces fresh regulatory scrutiny in South Africa as authorities examine the cost of digital media and communications services for consumers.

South Africa’s telecommunications regulator plans to investigate prices charged by so-called over-the-top service providers, including Netflix and Meta Platforms Inc.’s (NASDAQ:META) WhatsApp, Bloomberg reported on Monday, citing Business Day.

South Africa Reviews Digital Service CostsThe Independent Communications Authority of South Africa plans to assess what consumers pay for digital services as part of the inquiry, according to the report.

The regulator will separately investigate telecommunications-service costs, potentially affecting major operators including MTN Group Ltd., Vodacom Group Ltd., Telkom SA SOC Ltd. and Cell C Holdings Ltd.

South Africa’s telecommunications-service costs rank among the highest globally, according to the report.

Regulator Builds on Earlier Pricing ReviewsThe inquiry follows previous regulatory reviews of data-service costs and monitoring of prices after authorities allocated high-speed internet spectrum and introduced measures aimed at increasing competition.

The latest move also follows an effort by South Africa’s communications minister to bring in experts to identify policies and other interventions that could lower consumer prices.

The planned review places Netflix and other digital-service providers under closer scrutiny as regulators examine the affordability of services delivered over telecommunications networks.

The regulator had not provided additional comment when Bloomberg sought a response outside normal business hours.

Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price forecast of $90.67. Recent analyst moves include:

Wolfe Research: Outperform (Raises target to $95 on Aug. 25) Baird: Outperform (Lowers target to $90 on July 22) Morgan Stanley: Overweight (Lowers target to $83 on July 17) Top ETF Exposure REX FANG & Innovation Equity Premium Income ETF (NASDAQ:FEPI): 6.86% Weight Global X PureCap MSCI Communication Services ETF (NYSE:GXPC): 4.55% Weight Pathfinder Focused Opportunities ETF (NASDAQ:PFOE): 4.72% Weight Significance: Because Netflix carries such a heavy weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock.

NFLX Price ActionNetflix shares were down 2.28% at $76.47 at the time of publication on Tuesday, according to Benzinga Pro data.

Photo: Shutterstock

Read Next

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

3.94K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of NFLX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Streaming giant Netflix (NFLX -1.89%) told advertisers in May that its ad-supported plan now reaches more than 250 million monthly active viewers, up from 190 million last November.

And the money is following the audience. Management expects advertising revenue to roughly double this year, to about $3 billion. It's a small piece of the company's forecast of about $51 billion in total revenue for 2026 -- but easily the fastest-growing piece.

I don't think the doubling stops this year, either. I predict Netflix's advertising revenue passes $6 billion in 2027.

The case rests on three things the company already discloses: a growing viewer base, more countries to sell ads in, and ad revenue per viewer with plenty of room to rise.

Image source: Netflix.

The audience is still growing quicklyA monthly active viewer, in Netflix's definition, is a member who watched at least one minute of ads in a month, multiplied by the estimated number of people in that household. The household estimate comes from Netflix's own research, not a third-party firm.

The definition matters because it changed. In May 2025, Netflix counted 94 million monthly active users (profiles, not people), and Amy Reinhard, the company's president of advertising, said at the time that the figure translated to about 170 million viewers.

In other words, the audience didn't nearly triple over the past year, as the headline numbers suggest. Measured viewers against viewers -- a close but not perfect comparison -- it grew by about half. And that's still impressive growth for an audience this large.

The ad plan is also where new members go. Notably, Netflix said more than 60% of sign-ups choose it in the countries where it's available, and more than 80% of ad-plan members watch every week.

More countries are on the way, too. Starting next year, the plan is set to launch in 15 more, including Sweden, Poland, Indonesia, and the Philippines -- on top of the dozen markets where it sells ads today.

Can the revenue double again?In 2025, only the company's third year selling advertising, ad revenue grew to over $1.5 billion (more than 2.5 times its 2024 level). And this year's forecast calls for a rough doubling on top of that.

About $3 billion spread across more than 250 million viewers works out to about $12 per viewer a year, or about a dollar a month. Meanwhile, members pay $8.99 a month just for the U.S. ad plan's subscription, following a price increase in March. (That price is per account, while the ad figure counts every viewer in a household.) In other words, the advertising half of this business still brings in very little per viewer. Even doubling ad revenue on today's audience would only take that figure to about $2 a month.

Advertisers appear willing to pay up. Netflix said in August that commitments from its U.S. upfront (the annual negotiation in which advertisers lock in spending early) nearly doubled this year. Reinhard told advertisers in May that 44% of the members who see an ad on Netflix never see that ad on broadcast TV or other streaming services.

Sure, new ad markets typically start slowly, and a weak economy could cut advertising budgets faster than subscriptions. But if the audience keeps climbing and Netflix earns a bit more ad revenue per viewer, $6 billion is within reach.

Premium Feature

Moneyball Superscore

79/100

Today's Change

(

-1.89

%) $

-1.48

Current Price

$

76.77

Even $6 billion wouldn't fix everythingAdvertising matters this much because growth elsewhere is cooling. Netflix's second-quarter revenue grew 13% year over year, down from a 17.6% pace in the fourth quarter of 2025, and management forecasts 11.7% for the third quarter. Each quarter has been slower than the last.

Another doubling would mean about $3 billion of new revenue in 2027, or about 6 percentage points of growth on this year's forecast base. For the growth stock, that could be the difference between total growth sliding toward single digits and holding in the low teens.

What advertising can't do is carry the company. Advertising ultimately sells attention, and attention is barely growing. Netflix members watched more than 97 billion hours of content from January through June, up just 2% from the same period of 2025.

Even at $6 billion, advertising would be barely more than a tenth of the streaming service's revenue. Memberships and pricing still set Netflix's growth rate.

So, does Netflix's advertising revenue pass $6 billion in 2027? I believe it does. The audience keeps growing, and the ad revenue per viewer is still tiny.

As for Netflix stock, it trades near $77 as of this writing, or about 20 times expected 2027 earnings. That's arguably a reasonable price. But with growth cooling outside the ad line, I'll watch from the sidelines for now.

SAN FRANCISCO--(BUSINESS WIRE)--Today, Visa (NYSE: V) announced a new approach to onchain credit designed to help stablecoin-linked card programs and fintechs access working capital using onchain lending infrastructure and Visa data. Onchain lending has emerged as one of the fastest-growing segments of digital finance. According to the Visa Onchain Analytics Dashboard, since 2020, more than $694 billion in stablecoin-denominated loans have been sent through onchain lending protocols, creating a.

Visa (V - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Over the past month, shares of this global payments processor have returned +3.8%, compared to the Zacks S&P 500 composite's -0.4% change. During this period, the Zacks Financial Transaction Services industry, which Visa falls in, has lost 2.5%. The key question now is: What could be the stock's future direction?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Visa is expected to post earnings of $3.43 per share for the current quarter, representing a year-over-year change of +15.1%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.1%.

The consensus earnings estimate of $13.16 for the current fiscal year indicates a year-over-year change of +14.7%. This estimate has changed +0.1% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $14.98 indicates a change of +13.8% from what Visa is expected to report a year ago. Over the past month, the estimate has changed +0.2%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Visa.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of Visa, the consensus sales estimate of $12.07 billion for the current quarter points to a year-over-year change of +12.6%. The $45.83 billion and $50.62 billion estimates for the current and next fiscal years indicate changes of +14.6% and +10.4%, respectively.

Last Reported Results and Surprise HistoryVisa reported revenues of $11.63 billion in the last reported quarter, representing a year-over-year change of +14.4%. EPS of $3.32 for the same period compares with $2.98 a year ago.

Compared to the Zacks Consensus Estimate of $11.37 billion, the reported revenues represent a surprise of +2.28%. The EPS surprise was +2.79%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Visa is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Visa. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Visa Inc. (NYSE:V) expects millions of consumers to use AI agents to complete purchases by the 2026 holiday season. The question for investors is what happens when those agents start deciding not only what to buy, but how to pay for it.

In February, Citrini Research published a hypothetical scenario in which AI agents identified the cost attached to card transactions and shifted settlement toward cheaper stablecoin infrastructure. Visa, Mastercard Inc. (NYSE:MA), American Express Company (NYSE:AXP) and DoorDash Inc. (NYSE:DASH) fell after the report.

There is an important distinction in Visa’s case. The company does not earn the 2% to 3% interchange fee, which moves from acquirers to issuing banks. Visa says in its annual report that the fees it receives from issuers and acquirers are not derived from interchange or merchant discount rates.

The more serious bear case is that agents unbundle the payment stack. If an agent can choose a cheaper settlement rail while sourcing identity, authorization and fraud protection elsewhere, Visa loses volume without ever having collected the interchange fee.

Visa Wants To Make Its Trust Layer Harder To RemoveVisa launched Agentic Ready in Europe on March 17, then expanded it to Asia Pacific, Latin America and Canada. More than 50 issuers joined the Asia Pacific rollout alone. The program lets banks test enrollment, tokenization, authentication and transaction controls before agent-led purchases reach volume.

The strategic objective is to keep the credentials, permissions and protections surrounding an agent transaction attached to Visa’s infrastructure. Consumer caution helps that case. A Visa survey published in April found only 27% of Americans were comfortable letting an AI agent spend without limits, while 60% would not allow an agent to spend any amount without approval.

Early Tests And The Copyability ProblemIn December, Visa said it had completed hundreds of real-world agent-initiated transactions with more than 100 partners. DBS Group Holdings Ltd (OTC:DBSDF) has piloted agent-initiated purchases with Visa in Singapore, and on Aug. 19 DBS Hong Kong announced a partnership with Visa and Preface to extend that work to consumers.

For Visa, copyability cuts both ways. If no single bank can build a lasting moat around agentic features, value may migrate to the infrastructure that lets many banks deploy them. The opposite outcome is also possible: large banks could build more of the stack themselves and connect it to non-card rails. Mastercard is already there, having introduced Agent Pay for Machines in June to settle across cards, accounts and stablecoins.

Stablecoins Make Citrini’s Scenario More CredibleOn Sept. 1, 21 financial institutions including Bank of America, Citi, Goldman Sachs and Wells Fargo announced plans for a bank-issued dollar stablecoin targeting a first-half 2027 launch. The institutions on the issuing side of today’s card ecosystem are building another settlement option, and software can compare rails on every transaction in a way people do not.

Visa is hedging. It joined more than 140 companies behind the Open USD stablecoin in June and launched its own Stablecoin Platform in July. Its Intelligent Commerce Connect product, introduced in April, accepts both Visa and non-Visa cards across four agent protocols. The company appears to be preparing for a world in which the rail underneath a transaction changes while Visa still supplies the identity, tokenization and trust layer around it. That role may come with thinner economics.

What Investors Should WatchVisa enters this transition from strength. Fiscal third-quarter net revenue rose 14% to $11.6 billion, and processed transactions rose 10% to 71.7 billion. Agentic payments are far too small to move those numbers yet.

Watch how many Agentic Ready issuers move from testing into production, how quickly banks copy DBS, and whether Visa starts disclosing agent-initiated volume. The decisive evidence will come when an agent picks something other than a card. If Visa still earns on identity, authentication and orchestration in that transaction, Citrini’s scenario changes the business without displacing it. If those functions can be bought more cheaply elsewhere, the bear case gets much harder to dismiss.

Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Visa Inc. (V) Presents at Goldman Sachs Communacopia + Technology Conference 2026 Transcript

AST SpaceMobile Stock Soared 12%—This Was the CatalystVisa NYSE: V CEO Ryan McInerney said the payments company is seeing continued strength in consumer spending, accelerating cross-border activity and growing demand for cybersecurity, processing and other value-added services as it invests in artificial intelligence and new payment technologies.

Speaking at a company news event, McInerney attributed Visa’s performance to a strategy developed several years ago, organizational changes and execution by its global leadership team. He said Visa reorganized around areas including value-added services, CMS and consumer payments, while dedicating product and engineering teams to build and launch new offerings.

Get Visa alerts:

Vertiv’s UIG Deal Targets the Next Big Constraint in AI Data Centers“We have a strategy that’s working,” McInerney said. “We have a leadership team that’s very experienced and focused on executing that strategy. We have enormous opportunities ahead of us.”

Consumer Spending Remains Stable McInerney characterized consumer spending conditions as marked by “strength and stability,” despite uncertainty related to affordability, elections and broader economic conditions.

3 AI Infrastructure Stocks to Watch Beyond NVIDIAIn the U.S., Visa’s business has grown roughly 6% to 8% over the past year and a half, he said. The company’s U.S. business grew 10% in the most recent quarter and was growing about 9% quarter-to-date through the end of August. McInerney described Visa’s U.S. business as roughly $7 trillion in size.

Globally, payment transaction growth was running at approximately 10% year over year through the end of August, he said. Cross-border growth accelerated to about 14%, compared with approximately 12% in the prior quarter. E-commerce has continued to grow faster than travel, according to McInerney.

He also pointed to cross-border opportunities across consumer payments, Visa Direct and commercial payments. Visa Direct has 18 billion endpoints globally, including accounts, cards and wallets, McInerney said.

AI Adoption and Cybersecurity Demand McInerney said Visa has used artificial intelligence for decades and was an early adopter of generative AI tools following the emergence of ChatGPT. The company made a range of models and tools available to employees and provided training, support and coaching, he said.

According to McInerney, Visa has seen measurable productivity gains in its product and technology organizations, including:

An 80% increase in code commits; An 80% reduction in the time required to design and build a product; and Feature development occurring 65% faster. He said AI-related productivity improvements are also occurring across functions including human resources, marketing, finance, disputes and client service.

Cybersecurity has become one of the top three issues raised by clients worldwide, McInerney said. Visa participated in Project Glasswing and used the Mythos model to test for vulnerabilities, he said. While the company did not identify vulnerabilities that could be exploited externally, it identified internal system vulnerabilities and developed a “harness” intended to identify, remediate and fix issues.

Visa later open-sourced that harness through GitHub, according to McInerney. The company has also introduced the Visa Threat Intelligence Harness, which uses Visa’s cyber and fraud capabilities to help clients protect their environments.

McInerney said Visa’s planned acquisition of BioCatch would expand its ability to address identity-related risks before a transaction occurs. BioCatch serves companies with billions of users, he said.

Value-Added Services and Pismo Expansion McInerney said Visa’s value-added services businesses are performing well across issuer services, acceptance, risk and identity, and advisory offerings. He highlighted issuer benefits platforms, credential growth, tokenization and the Pismo platform as contributors to the company’s strategy.

Pismo, which Visa acquired after identifying demand for cloud-based banking technology and global issuer-processing capabilities, is being used to offer integrated debit, credit, prepaid and commercial issuer processing. In the U.S., McInerney said Visa sees an opportunity to combine Pismo with Visa DPS for small and midsize banks and fintechs seeking a single issuer-processing platform.

Visa expects larger and more sophisticated issuers to continue using separate, highly customized credit and debit stacks, he said, while Visa DPS remains positioned for debit processing.

On core banking, McInerney said relatively few large banks globally have moved their core systems to the cloud, but many are considering doing so. He said cloud-based core systems can enable banks to operate more agilely and introduce products more quickly.

Agentic Commerce, Stablecoins and Europe McInerney said consumers are increasingly using large language models for product discovery and comparison shopping, though autonomous payments have not yet gained comparable adoption. The principal barrier, he said, is trust among both merchants and consumers.

Visa is developing tools including the Trusted Agent Protocol and Trusted Agent Directory to help merchants identify legitimate, purpose-driven agents. McInerney said Visa planned to announce a “Visa Trust Index” the following day. He said research found that three out of four consumers do not trust agentic platforms to make payments independently using their financial information, while 61% said they would trust an agent to make payments if Visa were involved.

The company also sees product-market fit for stablecoins in countries where consumers and businesses seek access to U.S. dollars and in cross-border remittances and business-to-business payments. McInerney said Visa has more than 200 stablecoin issuance programs in 50 countries and is building capabilities across blockchains, issuance, wallets, infrastructure and applications.

In Europe, McInerney said Visa is responding to payment sovereignty concerns by investing locally. The company recently announced a €500 million incremental investment in the region, including a European data center, additional offices, a Frankfurt headquarters and an innovation center in Poland. He said the region remains highly competitive, with domestic card networks, digital wallets and the emerging Wero wallet offering alternatives.

McInerney said Visa’s recent workforce reduction was part of a multiyear effort to operate more efficiently and free resources for investments in marketing, product development, sales, offices and data centers.

About Visa (NYSE:V)Visa Inc is a global payments technology company that operates one of the world's largest electronic payment networks. The company connects consumers, businesses, financial institutions and governments, enabling transactions through credit, debit, prepaid and commercial payment products. Visa generally does not issue cards, extend credit or set consumer interest rates; instead, it provides the network, technology and services that support payments.

Visa's products and services include Visa-branded cards, digital payment solutions, tokenization, fraud prevention, risk management, data analytics and payment acceptance tools.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Visa Right Now?Before you consider Visa, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Visa wasn't on the list.

While Visa currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

SAN FRANCISCO--(BUSINESS WIRE)--Visa and the IFC are partnering on an innovative risk-sharing initiative.

Retail StocksThere are some opportunities for the company to tackle in streaming, but perhaps not as many as once hoped when Walmart acquired Vizio

Over the past few years, Walmart has quietly become a multibillion-dollar media company due to big investments in its advertising business.

That raises questions over how much the company might collaborate or compete with legacy media and entertainment giants in a bid to grow its empire even further, BofA analysts said on Tuesday.

Caitong International Asset Management Co. Ltd purchased a new stake in JPMorgan Chase & Co. (NYSE:JPM) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 2,876 shares of the financial services provider’s stock, valued at approximately $941,000.

Other hedge funds also recently bought and sold shares of the company. Morgan Stanley grew its holdings in JPMorgan Chase & Co. by 1.4% in the 4th quarter. Morgan Stanley now owns 66,385,268 shares of the financial services provider’s stock valued at $21,390,662,000 after buying an additional 939,421 shares during the last quarter. Bank of America Corp DE boosted its holdings in JPMorgan Chase & Co. by 15.8% in the 1st quarter. Bank of America Corp DE now owns 65,660,460 shares of the financial services provider’s stock valued at $19,314,681,000 after purchasing an additional 8,941,351 shares during the period. Norges Bank acquired a new stake in JPMorgan Chase & Co. in the 4th quarter worth $11,396,496,000. Bank of New York Mellon Corp raised its position in shares of JPMorgan Chase & Co. by 5.4% during the fourth quarter. Bank of New York Mellon Corp now owns 23,424,482 shares of the financial services provider’s stock valued at $7,547,837,000 after buying an additional 1,194,583 shares during the last quarter. Finally, Legal & General Group Plc lifted its stake in shares of JPMorgan Chase & Co. by 0.6% in the fourth quarter. Legal & General Group Plc now owns 19,019,564 shares of the financial services provider’s stock valued at $6,128,484,000 after buying an additional 110,586 shares during the period. 71.55% of the stock is currently owned by institutional investors.

JPMorgan Chase & Co. Stock Down 0.1% Shares of JPMorgan Chase & Co. stock opened at $358.21 on Tuesday. The business has a fifty day simple moving average of $350.46 and a 200 day simple moving average of $320.92. The stock has a market cap of $952.19 billion, a PE ratio of 15.35, a price-to-earnings-growth ratio of 1.48 and a beta of 0.98. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.30. JPMorgan Chase & Co. has a 12 month low of $279.10 and a 12 month high of $366.50.

JPMorgan Chase & Co. (NYSE:JPM – Get Free Report) last issued its earnings results on Tuesday, July 14th. The financial services provider reported $6.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.55. JPMorgan Chase & Co. had a return on equity of 18.23% and a net margin of 21.86%.The firm had revenue of $58.02 billion for the quarter, compared to analysts’ expectations of $50.72 billion. During the same quarter last year, the business earned $4.96 earnings per share. The company’s revenue was up 27.7% compared to the same quarter last year. Research analysts predict that JPMorgan Chase & Co. will post 24.28 EPS for the current year. JPMorgan Chase & Co. News Summary Here are the key news stories impacting JPMorgan Chase & Co. this week:

Positive Sentiment: JPMorgan strategist Marko Kolanovic reportedly recommended buying stock-market weakness, arguing that earnings strength could support equities. The commentary reinforces a constructive view of the broader market and JPMorgan’s investment-banking outlook. JPMorgan’s Matejka Says Buy the Dip in Stocks on Earnings Boost Positive Sentiment: A Zacks analysis identified JPM as a strong long-term stock, citing its positive earnings outlook and durable business quality. This supports investor confidence following JPMorgan’s recent earnings beat and substantial revenue growth. Why JPMorgan Chase & Co. (JPM) is a Top Stock for the Long-Term Neutral Sentiment: JPMorgan’s flagged 155 level in dollar-yen suggests a potential short squeeze as the yen strengthens. The resulting currency volatility could create trading opportunities for the bank but also reflects broader market-risk concerns. Dollar-Yen Falls To Seven-Month Lows: Is the Carry Trade Now Broken? Neutral Sentiment: JPMorgan said Europe’s proposed “transition” investment-fund label is too narrow. The issue could affect sustainable-finance product development, but no immediate earnings impact was indicated. JPMorgan Says Europe’s ‘Transition’ Fund Label Is Too Narrow Negative Sentiment: Analysts warned that fading capital-markets momentum in the third quarter could produce uneven results for major banks, including JPM. Weaker deal activity, trading or underwriting revenue would pressure near-term expectations. Capital Markets Momentum Fades: What it Means for Big Banks in Q3 Negative Sentiment: A valuation-focused analysis recommended accumulating JPMorgan preferred shares for income while holding the common stock, which it viewed as expensive at roughly 3.2 times book value. Elevated valuation limits upside if growth expectations weaken. JPMorgan: Start Accumulating The Preferred For Income, Hold The Common At 3.2x Book Negative Sentiment: Commentary on JPMorgan’s nearly $1 trillion market value highlighted investor dependence on CEO Jamie Dimon and uncertainty surrounding eventual succession. Any concern that the “Jamie premium” is too large could weigh on the common stock’s valuation. JPMorgan’s Market Value Is Flirting With $1 Trillion Wall Street Analysts Forecast Growth Several equities analysts have commented on JPM shares. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $418.00 price target on shares of JPMorgan Chase & Co. in a report on Tuesday, July 14th. Bank of America raised their price objective on shares of JPMorgan Chase & Co. from $408.00 to $420.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Royal Bank Of Canada upped their target price on shares of JPMorgan Chase & Co. from $330.00 to $370.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Morgan Stanley restated a “positive” rating and set a $370.00 target price on shares of JPMorgan Chase & Co. in a research report on Wednesday, July 15th. Finally, UBS Group upped their price target on JPMorgan Chase & Co. from $384.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eleven have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $359.96.

View Our Latest Stock Report on JPM

Insider Transactions at JPMorgan Chase & Co. In other news, General Counsel Stacey Friedman sold 5,467 shares of JPMorgan Chase & Co. stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $330.73, for a total transaction of $1,808,100.91. Following the transaction, the general counsel owned 40,961 shares in the company, valued at $13,547,031.53. The trade was a 11.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Robin Leopold sold 2,500 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $361.41, for a total value of $903,525.00. Following the sale, the insider directly owned 73,547 shares of the company’s stock, valued at approximately $26,580,621.27. The trade was a 3.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.41% of the company’s stock.

JPMorgan Chase & Co. Company Profile (Free Report)

JPMorgan Chase & Co (NYSE: JPM) is a diversified global financial services firm headquartered in New York City. The company provides a wide range of banking and financial products and services to consumers, small businesses, corporations, governments and institutional investors worldwide. Its operations span retail banking, commercial lending, investment banking, asset management, payments and card services, and treasury and securities services.

The firm’s principal business activities are organized across several core lines: Consumer & Community Banking, which offers deposit accounts, mortgages, auto loans, credit cards and branch and digital banking under the Chase brand; Corporate & Investment Banking, which provides capital markets, advisory, underwriting, trading and risk management services; Commercial Banking, delivering lending, treasury and capital solutions to middle-market and corporate clients; and Asset & Wealth Management, which offers investment management, private banking and retirement services to institutions and high-net-worth individuals.

Further Reading Five stocks we like better than JPMorgan Chase & Co. 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding JPM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for JPMorgan Chase & Co. (NYSE:JPM – Free Report).

Receive News & Ratings for JPMorgan Chase & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JPMorgan Chase & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

MASTERINVEST Kapitalanlage GmbH trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 9.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 30,423 shares of the company’s stock after selling 3,206 shares during the period. MASTERINVEST Kapitalanlage GmbH’s holdings in Johnson & Johnson were worth $7,727,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of JNJ. Auto Owners Insurance Co lifted its stake in Johnson & Johnson by 22,225.6% during the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after buying an additional 69,108,368 shares in the last quarter. Norges Bank purchased a new position in shares of Johnson & Johnson in the fourth quarter worth approximately $6,924,523,000. Capital World Investors acquired a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $2,005,942,000. Jupiter Topco LLC purchased a new stake in shares of Johnson & Johnson in the 2nd quarter valued at approximately $1,967,399,000. Finally, Diamant Asset Management Inc. lifted its position in shares of Johnson & Johnson by 24,436.5% in the 1st quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock valued at $109,338,000 after acquiring an additional 4,454,778 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson In other Johnson & Johnson news, EVP Kathryn Wengel sold 10,000 shares of the stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares in the company, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 97,569 shares of company stock valued at $25,476,044 in the last three months. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Down 0.0% NYSE:JNJ opened at $275.12 on Tuesday. The company has a market capitalization of $663.01 billion, a P/E ratio of 31.88, a P/E/G ratio of 2.63 and a beta of 0.24. The stock’s 50 day moving average price is $262.32 and its 200 day moving average price is $245.30. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. Johnson & Johnson has a 52 week low of $173.33 and a 52 week high of $281.07. Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company’s revenue was up 6.6% compared to the same quarter last year. During the same period in the previous year, the company earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, research analysts forecast that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be issued a $1.34 dividend. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. Johnson & Johnson’s dividend payout ratio is currently 62.11%.

Analyst Ratings Changes Several equities analysts have weighed in on the stock. UBS Group assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, September 2nd. They set a “buy” rating and a $320.00 price objective on the stock. HSBC set a $290.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research report on Monday, July 6th. Bank of America upped their price target on Johnson & Johnson from $254.00 to $263.00 and gave the company a “neutral” rating in a research report on Friday, July 10th. Raymond James Financial set a $280.00 price objective on Johnson & Johnson in a research report on Monday, August 3rd. Finally, Citigroup lifted their target price on Johnson & Johnson from $285.00 to $298.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $272.83.

Check Out Our Latest Stock Analysis on Johnson & Johnson

Johnson & Johnson Company Profile (Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Featured Articles Five stocks we like better than Johnson & Johnson 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Equitable Holdings Inc. reduced its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 15.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 144,824 shares of the company’s stock after selling 25,728 shares during the quarter. Equitable Holdings Inc.’s holdings in Johnson & Johnson were worth $36,781,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Centaurus Financial Inc. raised its position in Johnson & Johnson by 49.5% in the second quarter. Centaurus Financial Inc. now owns 12,384 shares of the company’s stock valued at $3,145,000 after purchasing an additional 4,103 shares during the period. Graybill Wealth Management LTD. boosted its holdings in Johnson & Johnson by 1.6% during the 2nd quarter. Graybill Wealth Management LTD. now owns 29,954 shares of the company’s stock valued at $7,607,000 after acquiring an additional 479 shares during the period. Fayez Sarofim & Co grew its position in Johnson & Johnson by 5.7% in the 2nd quarter. Fayez Sarofim & Co now owns 688,542 shares of the company’s stock valued at $174,869,000 after acquiring an additional 37,213 shares in the last quarter. Redwood Investment Management LLC increased its stake in Johnson & Johnson by 4.6% during the second quarter. Redwood Investment Management LLC now owns 5,960 shares of the company’s stock worth $1,514,000 after purchasing an additional 263 shares during the period. Finally, Parvin Asset Management LLC lifted its position in shares of Johnson & Johnson by 6.1% during the second quarter. Parvin Asset Management LLC now owns 3,470 shares of the company’s stock worth $881,000 after purchasing an additional 200 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets Several research analysts have recently issued reports on JNJ shares. Guggenheim upped their price objective on Johnson & Johnson from $270.00 to $287.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Argus set a $300.00 target price on shares of Johnson & Johnson in a research report on Wednesday, July 29th. TD Cowen lifted their price target on shares of Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Morgan Stanley raised their price objective on Johnson & Johnson from $284.00 to $294.00 and gave the stock an “overweight” rating in a report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $272.83.

View Our Latest Analysis on JNJ Insider Transactions at Johnson & Johnson In other news, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the sale, the executive vice president directly owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 97,569 shares of company stock valued at $25,476,044 over the last 90 days. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance Johnson & Johnson stock opened at $275.12 on Tuesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The business has a 50 day simple moving average of $262.32 and a 200-day simple moving average of $245.30. Johnson & Johnson has a 12 month low of $173.33 and a 12 month high of $281.07. The stock has a market capitalization of $663.01 billion, a PE ratio of 31.88, a price-to-earnings-growth ratio of 2.63 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. During the same period last year, the firm posted $2.77 EPS. Johnson & Johnson’s quarterly revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities analysts predict that Johnson & Johnson will post 11.61 earnings per share for the current year.

Johnson & Johnson Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 62.11%.

(Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Featured Articles Five stocks we like better than Johnson & Johnson 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Empowered Funds LLC raised its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 11.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 348,850 shares of the company’s stock after purchasing an additional 36,477 shares during the quarter. Johnson & Johnson accounts for approximately 0.5% of Empowered Funds LLC’s holdings, making the stock its 27th largest holding. Empowered Funds LLC’s holdings in Johnson & Johnson were worth $88,597,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. State Street Corp lifted its stake in Johnson & Johnson by 1.3% in the 4th quarter. State Street Corp now owns 133,869,843 shares of the company’s stock valued at $27,704,364,000 after acquiring an additional 1,663,782 shares in the last quarter. Auto Owners Insurance Co grew its stake in shares of Johnson & Johnson by 22,225.6% during the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after acquiring an additional 69,108,368 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Johnson & Johnson by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company’s stock valued at $11,967,947,000 after purchasing an additional 1,738,292 shares during the last quarter. Norges Bank bought a new stake in shares of Johnson & Johnson in the fourth quarter worth $6,924,523,000. Finally, Wellington Management Group LLP lifted its position in shares of Johnson & Johnson by 3.8% in the third quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company’s stock worth $4,789,914,000 after purchasing an additional 956,239 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets JNJ has been the topic of several analyst reports. Freedom Capital raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 16th. Citigroup raised their price objective on Johnson & Johnson from $285.00 to $298.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. UBS Group started coverage on Johnson & Johnson in a report on Wednesday, September 2nd. They set a “buy” rating and a $320.00 target price on the stock. Royal Bank Of Canada increased their price target on Johnson & Johnson from $265.00 to $287.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Finally, Scotiabank restated an “outperform” rating and issued a $305.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $272.83.

Get Our Latest Stock Report on JNJ Johnson & Johnson Stock Down 0.0% JNJ stock opened at $275.12 on Tuesday. Johnson & Johnson has a 1-year low of $173.33 and a 1-year high of $281.07. The business’s 50 day simple moving average is $262.32 and its 200 day simple moving average is $245.30. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $663.01 billion, a PE ratio of 31.88, a PEG ratio of 2.63 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. During the same quarter last year, the firm posted $2.77 EPS. The company’s quarterly revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, research analysts anticipate that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be paid a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.11%.

Insider Activity at Johnson & Johnson In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This represents a 7.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 97,569 shares of company stock worth $25,476,044 in the last quarter. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Profile (Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Featured Stories Five stocks we like better than Johnson & Johnson 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Fulcrum Asset Management LLP reduced its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 9.0% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 20,815 shares of the company’s stock after selling 2,061 shares during the period. Fulcrum Asset Management LLP’s holdings in Johnson & Johnson were worth $5,381,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. State Street Corp boosted its holdings in Johnson & Johnson by 1.3% during the fourth quarter. State Street Corp now owns 133,869,843 shares of the company’s stock worth $27,704,364,000 after buying an additional 1,663,782 shares in the last quarter. Auto Owners Insurance Co increased its holdings in Johnson & Johnson by 22,225.6% in the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after buying an additional 69,108,368 shares in the last quarter. Geode Capital Management LLC increased its holdings in Johnson & Johnson by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company’s stock valued at $11,967,947,000 after buying an additional 1,738,292 shares in the last quarter. Norges Bank acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at approximately $6,924,523,000. Finally, Wellington Management Group LLP lifted its position in shares of Johnson & Johnson by 3.8% during the 3rd quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company’s stock valued at $4,789,914,000 after acquiring an additional 956,239 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades A number of equities research analysts recently weighed in on JNJ shares. Bank of America upped their price target on Johnson & Johnson from $254.00 to $263.00 and gave the stock a “neutral” rating in a report on Friday, July 10th. TD Cowen lifted their price objective on Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Leerink Partners raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 target price on the stock in a report on Wednesday, May 13th. Scotiabank reaffirmed an “outperform” rating and set a $305.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. Finally, Morgan Stanley increased their price objective on shares of Johnson & Johnson from $284.00 to $294.00 and gave the company an “overweight” rating in a research note on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $272.83.

Read Our Latest Research Report on Johnson & Johnson Insider Buying and Selling In related news, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the transaction, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the transaction, the executive vice president directly owned 16,994 shares of the company’s stock, valued at approximately $4,367,458. This represents a 48.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 97,569 shares of company stock worth $25,476,044 in the last three months. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Trading Down 0.0% Johnson & Johnson stock opened at $275.12 on Tuesday. The stock has a market cap of $663.01 billion, a PE ratio of 31.88, a P/E/G ratio of 2.63 and a beta of 0.24. The stock has a 50-day moving average price of $262.32 and a 200 day moving average price of $245.30. Johnson & Johnson has a 52 week low of $173.33 and a 52 week high of $281.07. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. During the same period in the prior year, the firm earned $2.77 EPS. The firm’s quarterly revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities research analysts predict that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson’s payout ratio is presently 62.11%.

(Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Featured Articles Five stocks we like better than Johnson & Johnson 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Livforsakringsbolaget Skandia Omsesidigt lifted its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 4.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 222,206 shares of the company’s stock after purchasing an additional 10,400 shares during the quarter. Johnson & Johnson comprises about 1.8% of Livforsakringsbolaget Skandia Omsesidigt’s investment portfolio, making the stock its 11th biggest position. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Johnson & Johnson were worth $56,431,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Auto Owners Insurance Co increased its stake in Johnson & Johnson by 22,225.6% in the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after acquiring an additional 69,108,368 shares during the last quarter. Norges Bank purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $6,924,523,000. Capital World Investors bought a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $2,005,942,000. Jupiter Topco LLC purchased a new position in shares of Johnson & Johnson in the second quarter valued at $1,967,399,000. Finally, Diamant Asset Management Inc. increased its position in Johnson & Johnson by 24,436.5% in the first quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company’s stock worth $109,338,000 after purchasing an additional 4,454,778 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling In other Johnson & Johnson news, EVP Jennifer Taubert sold 15,000 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares of the company’s stock, valued at $51,210,615.36. This represents a 7.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 97,569 shares of company stock worth $25,476,044 over the last ninety days. Corporate insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades JNJ has been the subject of several research reports. Freedom Capital upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 16th. HSBC set a $290.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Monday, July 6th. Leerink Partners raised shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price target for the company in a report on Wednesday, May 13th. Bank of America lifted their price target on Johnson & Johnson from $254.00 to $263.00 and gave the stock a “neutral” rating in a research report on Friday, July 10th. Finally, Guggenheim boosted their price objective on Johnson & Johnson from $270.00 to $287.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $272.83. View Our Latest Research Report on JNJ

Johnson & Johnson Price Performance Johnson & Johnson stock opened at $275.12 on Tuesday. The firm has a 50-day moving average price of $262.32 and a 200-day moving average price of $245.30. The firm has a market capitalization of $663.01 billion, a PE ratio of 31.88, a price-to-earnings-growth ratio of 2.63 and a beta of 0.24. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12-month low of $173.33 and a 12-month high of $281.07.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. During the same period in the prior year, the firm posted $2.77 EPS. The firm’s revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. Johnson & Johnson’s payout ratio is presently 62.11%.

(Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Read More Five stocks we like better than Johnson & Johnson 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

First presentation of pivotal Phase 3 CAPLYTA ® data in adults with bipolar mania underscores the asset's potential across mood disorders

New SPRAVATO ® analyses and schizophrenia research emphasize a focus on complex, high-burden neuropsychiatric conditions

, /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that 24 abstracts featuring clinical data and real-world evidence across the neuropsychiatry portfolio will be presented at the 2026 Psych Congress Annual Meeting (September 15-19, New Orleans, LA).

Among the featured presentations are new pivotal Phase 3 data evaluating the efficacy and safety of CAPLYTA® (lumateperone) in bipolar mania, alongside additional CAPLYTA® data across bipolar depression and major depressive disorder that further reinforce the breadth of studies for the asset across mood disorders. Data evaluating the effect of SPRAVATO® (esketamine) CIII nasal spray on depressive symptoms such as anhedonia, and Phase 3 clinical trial data for seltorexant in major depressive disorder (MDD) with insomnia symptoms will also be presented. Together, the presentations reflect the Company's continued commitment to advancing research across mood disorders, with a focus on areas where patients and clinicians still face significant treatment challenges.

"People living with neuropsychiatric disorders often face complex, overlapping symptoms that can make identification, treatment selection and long-term management especially challenging," said Jane Tiller, MD, Vice President, Global Head of Development, Neuroscience, Johnson & Johnson. "By advancing clinical and real-world evidence across our portfolio and pipeline, we aim to help move psychiatry forward so that clinicians can continue to make more informed decisions for the patients they serve."

Psych Congress Annual Meeting highlights include:

CAPLYTA®  New data from a pivotal Phase 3 study investigating CAPLYTA® in the acute treatment of patients with manic episodes or manic episodes with mixed features associated with bipolar I disorder will be presented,1 alongside additional data evaluating adjunctive CAPLYTA® in MDD across depressive symptoms, remission, patient subgroups, and metabolic outcomes.2-8 New real-world evidence study evaluating treatment patterns among patients with bipolar depression receiving CAPLYTA®, including dosing and duration in line with routine clinical practice.9 SPRAVATO®  New analyses examining real-world evidence on the impact of SPRAVATO® in treating anhedonia, a core symptom of depression associated with poorer treatment outcomes.10,11 Long-acting Injectables (LAIs) Real-world studies evaluating schizophrenia-related hospitalizations in young dual-eligible patients prior to LAI initiation and subsequent risk of relapse, as well as treatment satisfaction with LAIs.12,13 Seltorexant Real-world data providing insights into MDD with insomnia symptoms, including disease burden, patient management and treatment outcomes.14-16 The full list of Johnson & Johnson data presentations at Psych Congress is available on JNJ.com. The Company will also support a variety of educational programs, in-booth presentations and training opportunities for attendees, including interactive visualizations of PRIDE LAI data, and the latest CAPLYTA® schizophrenia and network meta-analysis (NMA) findings.

ABOUT BIPOLAR MANIA
Bipolar disorder affects an estimated 37 million people worldwide—approximately 1 in 200 individuals—with 4.4% of U.S. adults experiencing the condition in their lifetime.17,18 Mania, a key feature of Bipolar I disorder, is characterized by at least a week-long period of elevated or irritable mood and/or increased energy, as well as symptoms including grandiosity, decreased need for sleep, racing thoughts, distractibility, and risk-taking behavior.19 These noticeable behavioral changes often differ markedly from an individual's baseline and are frequently first recognized by those close to them. In severe cases, manic episodes may require hospitalization for safety and treatment.20

ABOUT MAJOR DEPRESSIVE DISORDER (MDD)
MDD is one of the most common psychiatric disorders and a leading cause of disability worldwide, impacting an estimated 332 million people—or about 4 percent of the population.21,22,23 In 2023, approximately 22 million adults in the U.S. had at least one major depressive episode.24 While depression is typically treated with a "one-size-fits-all" approach, no two cases are the same. MDD is a complex, heterogeneous disorder involving multiple regions of the brain and presenting with as many as 256 unique symptom combinations. As a result, responses to treatment vary widely.25,26 Only 1 in 3 patients reach remission with their first antidepressant—and rates continue to decline further with each subsequent treatment, leaving many to spend years cycling through multiple treatments trying to find complete, sustained symptom relief.27 Moreover, MDD is a risk factor for the development and worsening of a range of comorbidities, illustrating the importance of integrating mental and general health care.28

Anhedonia, a loss of interest or pleasure in previously enjoyed activities, is one of two defining symptoms of a major depressive episode.29 Anhedonia is associated with poorer treatment outcomes, including lower remission rates, greater functional impairment, and higher suicide risk.30 Notably, 40-70% of people with MDD experience anhedonia.30

MDD often includes sleep disturbances such as insomnia or hypersomnia, with approximately 60 percent of MDD patients experiencing clinically relevant insomnia symptoms despite being on an SSRI/SNRI.31 Disturbed sleep and insomnia symptoms have a significant impact on a patient's quality of life and exacerbate the risk of depressive relapse and suicide.32,33

Approximately one-third of adults with MDD will not respond to oral antidepressants alone and are considered to have treatment-resistant depression (TRD), which is often defined as inadequate response to two or more oral antidepressants that were administered at an adequate dose for an adequate duration.34,35 TRD has a significant negative impact on the lives of those affected and has one of the highest economic burdens of all psychiatric disorders.35 Patients often cycle through multiple oral medications, waiting 4-6 weeks for potential relief.36 Based on the STAR*D study, after their third line of treatment, approximately 86 percent of patients do not achieve remission.36

ABOUT SCHIZOPHRENIA
Schizophrenia is a complex, chronic brain disorder that affects how people think, feel, speak, and act. It affects up to an estimated 2.8 million adults in the United States yet remains widely misunderstood and insufficiently treated.37 Symptoms vary by person, but confusion and distortions in perceptions, emotions, and behavior are common.38 Evidence shows that the first three to five years after diagnosis — "the critical period" — from symptom onset are key for a patient's treatment, as this is when the condition progresses most rapidly.39,40 A comprehensive treatment plan, which may include medication, therapy, and psychosocial services, is critical in delaying the time to relapse for adults with schizophrenia.41

ABOUT CAPLYTA® (lumateperone)
CAPLYTA® 42 mg is an oral, once daily atypical antipsychotic approved in adults as an adjunctive therapy with antidepressants for major depressive disorder (MDD), schizophrenia, and depressive episodes associated with bipolar I or II disorder (bipolar depression), as monotherapy, or as adjunctive therapy with lithium or valproate.

While the mechanism of action of CAPLYTA® is unknown, the efficacy of CAPLYTA® could be mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and partial agonist activity at central dopamine D2 receptors.

A supplemental New Drug Application (sNDA) for CAPLYTA® with long-term data evaluating the safety and efficacy of the medication for delayed time to relapse in schizophrenia was recently approved by the U.S. Food and Drug Administration. The medication is also being studied for other neuropsychiatric disorders. CAPLYTA® is not FDA-approved for these disorders.

ABOUT SPRAVATO® (esketamine) CIII NASAL SPRAY
SPRAVATO® is approved by the U.S. Food and Drug Administration as monotherapy or in conjunction with an oral antidepressant for adults with MDD when they have inadequate response to at least two oral antidepressants (TRD) and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior in conjunction with an oral antidepressant. It is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor and is believed to work differently than traditional antidepressants by acting on a pathway in the brain that affects glutamate. The mechanism by which esketamine exerts its antidepressant effect is unknown. To date, SPRAVATO® has been approved in over 70 markets and administered to more than 250,000 patients worldwide.

ABOUT J&J'S SCHIZOPHRENIA LONG-ACTING INJECTABLE (LAI) PORTFOLIO
Johnson & Johnson's portfolio of long-acting injectable (LAI) offerings for schizophrenia offers a varied range of dosing options and the longest-lasting schizophrenia treatments with each dose available, including INVEGA SUSTENNA® (1-month paliperidone palmitate), INVEGA TRINZA® (3-month paliperidone palmitate), and INVEGA HAFYERA® (6-month paliperidone palmitate), all of which are administered in a clinical setting by a medical professional.42,43,44

ABOUT SELTOREXANT
Seltorexant, an investigational first-in-class therapy, is a selective antagonist of the human orexin-2 receptor currently being developed as an adjunctive treatment for adults with MDD with insomnia symptoms. Seltorexant selectively antagonizes the orexin-2 receptors, potentially improving mood symptoms associated with depression and restoring sleep without next-day sedation.45 When orexin-2 receptors are stimulated for too long or at inappropriate times, their activation can cause hyperarousal manifestations, including insomnia and excessive cortisol release, which may contribute to depression.46,47 Seltorexant is the only investigational therapy under study for the treatment of MDD that is believed to work by normalizing the overactivation of the orexin-2 receptors, thereby targeting the underlying biology that contributes to depression and insomnia symptoms.

CAPLYTA® IMPORTANT SAFETY INFORMATION

What is CAPLYTA (lumateperone)?

CAPLYTA® (lumateperone) is a prescription medicine used in adults along with an antidepressant to treat major depressive disorder (MDD); to treat depressive episodes associated with bipolar I or bipolar II disorder (bipolar depression) alone or with lithium or valproate; or to treat schizophrenia. It is not known if CAPLYTA is safe and effective in children.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about CAPLYTA?

Medicines like CAPLYTA can raise the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). CAPLYTA is not approved for treating people with dementia-related psychosis. CAPLYTA and antidepressant medicines increase the risk of suicidal thoughts and actions in people 24 years of age and younger, especially within the first few months of treatment or when the dose is changed. Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Patients and their families or caregivers should watch for new or worsening depression symptoms, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when CAPLYTA or an antidepressant medicine is started or when the dose is changed. Report any changes in these symptoms to your healthcare provider immediately. • thoughts about suicide or dying     

• acting aggressive, being angry or violent 

• panic attacks

• new or worse depression 

• new or worse anxiety

• new or worse irritability  

• feeling very agitated or restless   

• suicide attempts 

• acting on dangerous impulses

• trouble sleeping

• an extreme increase in activity and talking (mania)

• other unusual changes in behavior or mood

Do not take CAPLYTA if you are allergic to any of its ingredients. Get emergency medical help if you are having an allergic reaction (e.g., rash, itching, hives, swelling of the tongue, lip, face, or throat).

What are the possible side effects of CAPLYTA?

CAPLYTA may cause serious side effects, including:

Stroke (cerebrovascular problems) in elderly people with dementia-related psychosis that can lead to death. Neuroleptic malignant syndrome (NMS): high fever, confusion, changes in your breathing, heart rate, and blood pressure, stiff muscles, and increased sweating; these may be symptoms of a rare but potentially fatal condition. Contact your healthcare provider or go to the emergency room if you experience signs and symptoms of NMS. Uncontrolled body movements (tardive dyskinesia, TD) in your face, tongue, or other body parts. TD may not go away, even if you stop taking CAPLYTA. It may also occur after you stop taking CAPLYTA. Problems with your metabolism including high blood sugar, diabetes, increased fat (cholesterol and triglyceride) levels in your blood and weight gain. Your healthcare provider should check your blood sugar, fat levels, and weight before you start and during your treatment with CAPLYTA. Extremely high blood sugar levels can lead to coma or death. Call your healthcare provider if you have any of the following symptoms of high blood sugar: feeling very thirsty, hungry, sick to your stomach, needing to urinate more than usual, weak/tired, or confused, or your breath smells fruity. Low white blood cell count. Your healthcare provider may do blood tests during the first few months of treatment with CAPLYTA. Decreased blood pressure (orthostatic hypotension). You may feel lightheaded, dizzy, or faint when you rise too quickly from a sitting or lying position. Falls. CAPLYTA may make you sleepy or dizzy, may cause a decrease in your blood pressure when changing position (orthostatic hypotension), and can slow your thinking and motor skills which may lead to falls that can cause broken bones or other injuries. Seizures (convulsions). Sleepiness, drowsiness, feeling tired, difficulty thinking and doing normal activities. Until you know how CAPLYTA affects you, do not drive, operate heavy machinery, or do other dangerous activities. Problems controlling your body temperature so that you feel too warm. Avoid getting overheated or dehydrated while taking CAPLYTA. Difficulty swallowing that can cause food or liquid to get into the lungs. The most common side effects of CAPLYTA include sleepiness, dizziness, nausea, dry mouth, feeling tired, and diarrhea.

These are not all the possible side effects of CAPLYTA.

Before taking CAPLYTA, tell your healthcare provider about all of your medical conditions, including if you: have or have had heart problems or a stroke, high or low blood pressure, diabetes, or high blood sugar, problems with cholesterol, have or have had a low white blood cell count, seizures (convulsions), or kidney or liver problems.

CAPLYTA may cause fertility problems in females and males. You should notify your healthcare provider if you become pregnant or intend to become pregnant while taking CAPLYTA. There is a pregnancy registry for females who are exposed to CAPLYTA during pregnancy. CAPLYTA may cause abnormal involuntary movements and/or withdrawal symptoms in newborn babies exposed to CAPLYTA during the third trimester. Talk to your healthcare provider if you breastfeed or are planning to breastfeed as CAPLYTA passes into breast milk.

Tell your healthcare provider about all the medicines you're taking. CAPLYTA may affect the way other medicines work, and other medicines may affect how CAPLYTA works, causing possible serious side effects. Do not start or stop any medicines while taking CAPLYTA without talking to your healthcare provider. You are encouraged to report negative side effects of prescription drugs. Contact Intra-Cellular Therapies, Inc. at 1-800-526-7736 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

CAPLYTA is available in 42 mg, 21 mg, and 10.5 mg capsules.

Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for CAPLYTA.

cp-548761v3

INVEGA SUSTENNA®, INVEGA TRINZA®, INVEGA HAFYERA® IMPORTANT SAFETY INFORMATION 

INDICATIONS 

INVEGA HAFYERA® (6-month paliperidone palmitate) is a prescription medicine given by injection every 6 months by a healthcare professional and used to treat schizophrenia. INVEGA HAFYERA® is used in adults who have been treated with either: 

INVEGA SUSTENNA® (paliperidone palmitate) a 1-time-each-month paliperidone palmitate extended-release injectable suspension for at least 4 months  INVEGA TRINZA® (paliperidone palmitate) a 1-time-every-3-months paliperidone palmitate extended-release injectable suspension for at least 3 months  INVEGA TRINZA® is a prescription medicine given by injection every 3 months by a healthcare professional and used to treat schizophrenia. INVEGA TRINZA® is used in people who have been adequately treated with INVEGA SUSTENNA® for at least 4 months. 

INVEGA SUSTENNA® is a prescription medicine given by injection by a healthcare professional.  

INVEGA SUSTENNA® is used to treat schizophrenia in adults. 

IMPORTANT SAFETY INFORMATION 

What is the most important information I should know about INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA®? 

INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® may cause serious side effects, including: 

Increased risk of death in elderly people with dementia-related psychosis. 
INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® increase the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® are not for the treatment of people with dementia-related psychosis.  Do not receive INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® if you are allergic to paliperidone, paliperidone palmitate, risperidone, or any of the ingredients in INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®. See the end of the Patient Information leaflet in the full Prescribing Information for a complete list of INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® ingredients. 

Before you receive INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®, tell your healthcare professional about all your medical conditions, including if you:   

have had Neuroleptic Malignant Syndrome (NMS)  have or have had heart problems, including a heart attack, heart failure, abnormal heart rhythm, or long QT syndrome  have or have had low levels of potassium or magnesium in your blood  have or have had uncontrolled movements of your tongue, face, mouth, or jaw (tardive dyskinesia)  have or have had kidney or liver problems  have diabetes or have a family history of diabetes  have Parkinson's disease or a type of dementia called Lewy Body Dementia  have had a low white blood cell count  have had problems with dizziness or fainting or are being treated for high blood pressure  have or have had seizures or epilepsy  have any other medical conditions  are pregnant or plan to become pregnant. It is not known if INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® will harm your unborn baby  If you become pregnant while taking INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®, talk to your healthcare professional about registering with the National Pregnancy Registry for Atypical Antipsychotics. You can register by calling 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry.  Infants born to women who are treated with INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® may experience symptoms such as tremors, irritability, excessive sleepiness, eye twitching, muscle spasms, decreased appetite, difficulty breathing, or abnormal movement of arms and legs. Let your healthcare professional know if these symptoms occur.  are breastfeeding or plan to breastfeed. INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® 
can pass into your breast milk. Talk to your healthcare professional about the best way to feed your baby if you receive INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®.  Tell your healthcare professional about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® may affect the way other medicines work, and other medicines may affect how INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® works. 

Your healthcare provider can tell you if it is safe to receive INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® with your other medicines. Do not start or stop any medicines during treatment with INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® without talking to your healthcare provider first. Know the medicines you take. Keep a list of them to show to your healthcare professional or pharmacist when you get a new medicine. 

Patients (particularly the elderly) taking antipsychotics with certain health conditions or those on long-term therapy should be evaluated by their healthcare professional for the potential risk of falls. 

How will I receive INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®? 

Follow your treatment schedule exactly as your healthcare provider tells you to.  Your healthcare provider will tell you how much you will receive and when you will receive it.  What should I avoid while receiving INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®? 

INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® may affect your ability to make decisions, think clearly, or react quickly. Do not drive, operate heavy machinery, or do other dangerous activities until you know how INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® affects you.  Avoid getting overheated or dehydrated.   INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® may cause serious side effects, including: 

See "What is the most important information I should know about INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA®?"  stroke in elderly people (cerebrovascular problems) that can lead to death  Neuroleptic Malignant Syndrome (NMS). NMS is a rare but very serious problem that can happen in people who receive INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®. NMS can cause death and must be treated in a hospital. Call your healthcare professional right away if you become severely ill and have any of these symptoms: high fever; severe muscle stiffness; confusion; loss of consciousness; changes in your breathing, heartbeat, and blood pressure.  problems with your heartbeat. These heart problems can cause death. Call your healthcare professional right away if you have any of these symptoms: passing out or feeling like you will pass out, dizziness, or feeling as if your heart is pounding or missing beats.  uncontrolled movements of your tongue, face, mouth, or jaw (tardive dyskinesia)  metabolic changes. Metabolic changes may include high blood sugar (hyperglycemia), diabetes mellitus and changes in the fat levels in your blood (dyslipidemia), and weight gain.  low blood pressure and fainting  changes in your blood cell counts  high level of prolactin in your blood (hyperprolactinemia). INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® may cause a rise in the blood levels of a hormone called prolactin (hyperprolactinemia) that may cause side effects including missed menstrual periods, leakage of milk from the breasts, development of breasts in men, or problems with erection.   problems thinking clearly and moving your body  seizures  difficulty swallowing that can cause food or liquid to get into your lungs  prolonged or painful erection lasting more than 4 hours. Call your healthcare professional or go to your nearest emergency room right away if you have an erection that lasts more than 4 hours.   problems with control of your body temperature, especially when you exercise a lot or spend time doing things that make you warm. It is important for you to drink water to avoid dehydration.  The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory tract infections, feeling restlessness or difficulty sitting still, slow movements, tremors, stiffness and shuffling walk. 

The most common side effects of INVEGA TRINZA® include: injection site reactions, weight gain, headache, upper respiratory tract infections, feeling restlessness or difficulty sitting still, slow movements, tremors, stiffness and shuffling walk. 

The most common side effects of INVEGA SUSTENNA® include: injection site reactions; sleepiness or drowsiness; dizziness; feeling of inner restlessness or needing to be constantly moving; abnormal muscle movements, including tremor (shaking), shuffling, uncontrolled involuntary movements, and abnormal movements of your eyes. 

Tell your healthcare professional if you have any side effect that bothers you or does not go away. These are not all the possible side effects of INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA®. For more information, ask your healthcare professional or pharmacist. 

Call your healthcare professional for medical advice about side effects. You may report side effects of prescription drugs to the FDA at 1-800-FDA-1088. 

General information about the safe and effective use of INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® 

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.

Do not use INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® for a condition for which it was not prescribed. You can ask your pharmacist or healthcare professional for information about INVEGA HAFYERA®, INVEGA TRINZA® or INVEGA SUSTENNA® that is written for healthcare professionals. 

For more information, go to www.invegahafyera.com, www.invegatrinza.com or www.invegasustenna.com or call 1-800-526-7736. 

Please click to read the full Prescribing Information, including Boxed WARNING, for INVEGA HAFYERA®, INVEGA TRINZA® and INVEGA SUSTENNA® and discuss any questions you have with your healthcare professional. 

cp-256259v4

SPRAVATO® IMPORTANT SAFETY INFORMATION 

What is SPRAVATO® (esketamine) CIII nasal spray? 

SPRAVATO® is a prescription medicine used:

with or without an antidepressant taken by mouth, to treat adults with treatment-resistant depression (TRD) with an antidepressant taken by mouth, to treat depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine.

It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.

It is not known if SPRAVATO® is safe and effective in children. 

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about SPRAVATO®? 

SPRAVATO® can cause serious side effects, including: 

Sedation, dissociation, and respiratory depression. SPRAVATO® may cause sleepiness (sedation), fainting, dizziness, spinning sensation, anxiety, or feeling disconnected from yourself, your thoughts, feelings, space and time (dissociation), breathing problems (respiratory depression and respiratory arrest) Tell your healthcare provider right away if you feel like you cannot stay awake or if you feel like you are going to pass out.  Your healthcare provider must monitor you for serious side effects for at least 2 hours after taking SPRAVATO®. Your healthcare provider will decide when you are ready to leave the healthcare setting.  Abuse and misuse. There is a risk for abuse and misuse with SPRAVATO®, which may lead to physical and psychological dependence. Your healthcare provider should check you for signs of abuse, misuse, and dependence before and during treatment. Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs.  Your healthcare provider can tell you more about the differences between physical and psychological dependence and drug addiction.  SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS). Because of the risks for sedation, dissociation, respiratory depression and abuse and misuse, SPRAVATO® is only available through a restricted program called the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program. SPRAVATO® can only be administered at healthcare settings certified in the SPRAVATO® REMS Program. Patients treated in outpatient healthcare settings (such as medical offices and clinics) must be enrolled in the program. Increased risk of suicidal thoughts and actions. Antidepressant medicines may increase suicidal thoughts and actions in some people 24 years of age and younger, especially within the first few months of treatment or when the dose is changed. SPRAVATO® is not for use in children. Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a higher risk of having suicidal thoughts or actions. These include people who have (or have a family history of) depression or a history of suicidal thoughts or actions.  How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?  Pay close attention to any changes, especially sudden changes, in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions.  Tell your healthcare provider right away if you have any new or sudden changes in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions.  Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms.  Tell your healthcare provider or get emergency help right away if you or your family member have any of the following symptoms, especially if they are new, worse, or worry you: 

thoughts about suicide or dying  new or worse depression  feeling very agitated or restless  trouble sleeping (insomnia)  acting aggressive, being angry or violent  an extreme increase in activity and talking (mania)  suicide attempts  new or worse anxiety  panic attacks  new or worse irritability  acting on dangerous impulses  other unusual changes in behavior or mood  Do not take SPRAVATO® if you: 

have blood vessel (aneurysmal vascular) disease (including in the brain, chest, abdominal aorta, arms and legs)  have an abnormal connection between your veins and arteries (arteriovenous malformation)  have a history of bleeding in the brain  are allergic to esketamine, ketamine, or any of the other ingredients in SPRAVATO®.  If you are not sure if you have any of the above conditions, talk to your healthcare provider before taking SPRAVATO®. 

Before you take SPRAVATO®, tell your healthcare provider about all of your medical conditions, including if you: 

have heart or brain problems, including:  high blood pressure (hypertension)  slow or fast heartbeats that cause shortness of breath, chest pain, lightheadedness, or fainting  history of heart attack  history of stroke  heart valve disease or heart failure  history of brain injury or any condition where there is increased pressure in the brain  have liver problems  have ever had a condition called "psychosis" (see, feel, or hear things that are not there, or believe in things that are not true).  are pregnant or plan to become pregnant. SPRAVATO® may harm your unborn baby. You should not take SPRAVATO® if you are pregnant.  Tell your healthcare provider right away if you become pregnant during treatment with SPRAVATO®.  If you are able to become pregnant, talk to your healthcare provider about methods to prevent pregnancy during treatment with SPRAVATO®.  There is a pregnancy registry for women who are exposed to SPRAVATO® during pregnancy. The purpose of the registry is to collect information about the health of women exposed to SPRAVATO® and their baby. If you become pregnant during treatment with SPRAVATO®, talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or online at https://womensmentalhealth.org/clinical-and-research- programs/pregnancyregistry/antidepressants/.  are breastfeeding or plan to breastfeed. SPRAVATO® passes into your breast milk. You should not breastfeed during treatment with SPRAVATO®.  Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking SPRAVATO® with certain medicines may cause side effects. 

Especially tell your healthcare provider if you take central nervous system (CNS) depressants, psychostimulants, or monoamine oxidase inhibitors (MAOIs) medicines. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine. 

How will I take SPRAVATO®? 

You will take SPRAVATO®  nasal spray yourself, under the supervision of a healthcare provider in a healthcare setting. Your healthcare provider will show you how to use the SPRAVATO® nasal spray device.  Your healthcare provider will tell you how much SPRAVATO® you will take and when you will take it.  Follow your SPRAVATO® treatment schedule exactly as your healthcare provider tells you to.  During and after each use of the SPRAVATO® nasal spray device, you will be checked by a healthcare provider who will decide when you are ready to leave the healthcare setting.  You will need to plan for a caregiver or family member to drive you home after taking SPRAVATO®.  If you miss a SPRAVATO® treatment, your healthcare provider may change your dose and treatment schedule.  Some people taking SPRAVATO® get nausea and vomiting. You should not eat for at least 2 hours before taking SPRAVATO® and not drink liquids at least 30 minutes before taking SPRAVATO®.  If you take a nasal corticosteroid or nasal decongestant medicine take these medicines at least 1 hour before taking SPRAVATO®.  What should I avoid while taking SPRAVATO®? 

Do not drive, operate machinery, or do anything where you need to be completely alert after taking SPRAVATO®. Do not take part in these activities until the next day following a restful sleep. See "What is the most important information I should know about SPRAVATO®?" 

What are the possible side effects of SPRAVATO®? 

SPRAVATO® may cause serious side effects including: 

See "What is the most important information I should know about SPRAVATO®?" 

Increased blood pressure. SPRAVATO® can cause a temporary increase in your blood pressure that may last for about 4 hours after taking a dose. Your healthcare provider will check your blood pressure before taking SPRAVATO® and for at least 2 hours after you take SPRAVATO®. Tell your healthcare provider right away if you get chest pain, shortness of breath, sudden severe headache, change in vision, or seizures after taking SPRAVATO®. 

Problems with thinking clearly. Tell your healthcare provider if you have problems thinking or remembering. 

Bladder problems. Tell your healthcare provider if you develop trouble urinating, such as a frequent or urgent need to urinate, pain when urinating, or urinating frequently at night. 

The most common side effects of SPRAVATO® include: 

feeling disconnected from yourself, your thoughts, feelings and things around you  dizziness  nausea  feeling sleepy  spinning sensation  decreased feeling of sensitivity (numbness)  feeling anxious  lack of energy  increased blood pressure  vomiting  feeling drunk  headache  feeling very happy or excited  If these common side effects occur, they usually happen right after taking SPRAVATO® and go away the same day. 

These are not all the possible side effects of SPRAVATO®. 

Call your doctor for medical advice about side effects. You may report side effects to Johnson & Johnson at 1-800-526-7736, or to the FDA at 1-800-FDA-1088. 

Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider. 

cp-170363v4 

About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.

Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Follow us at @JNJInnovMed.

© Johnson & Johnson and its affiliates 2026. All rights reserved.

Cautions Concerning Forward-Looking Statements 
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to product development and the potential benefits and treatment impact of CAPLYTA® (lumateperone), SPRAVATO® (esketamine) CIII nasal spray, and seltorexant. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

References:

Brown D, Chen C, Chen M, et al. Lumateperone Treatment for Manic Episodes or Manic Episodes With Mixed Features in Bipolar I Disorder: Results From a Double-Blind, Placebo-Controlled, Randomized, Phase 3 Trial. Psych Congress 2026 Annual Meeting; Sept. 15-19, 2026. Black D, Namjoshi M, Obando C, et al. Changes in Mean Total Score on the PHQ-9 Among Bipolar Depression Patients Treated with Lumateperone in the United States: An Electronic Health Records Study. Psych Congress 2026 Annual Meeting; Sept. 15-19, 2026. Chen C, Durgam S, Earley WR, et al. Adjunctive Lumateperone 42 mg Treatment in Major Depressive Disorder: A Pooled Analysis of Efficacy Across Patient-Reported Depression Symptoms. Psych Congress 2026 Annual Meeting; Sept. 15-19, 2026. Armas-Datorre J, Durgam S, Earley WR, et al. Lumateperone 42 mg in Major Depressive Disorder: Demographic and Clinical Subgroups Efficacy Analysis in a Phase 3 Randomized Placebo-Controlled Trial. Psych Congress 2026 Annual Meeting; Sept. 15-19, 2026. Bhagwagar Z, Chen C, Durgam S, et al. Lumateperone 42 mg in Patients With Major Depressive Disorder: Analysis of Remission in Short- and Long-Term Trials. Psych Congress 2026 Annual Meeting; Sept. 15-19, 2026. Dutheil S, Snyder G. Assessment of Lumateperone Partial Agonist Activity at Presynaptic Dopamine D2 Autoreceptors: Reversal of Haloperidol-Induced Tyrosine Hydroxylase Phosphorylation in Mouse Striatum. Psych Congress 2026 Annual Meeting; Sept. 15-19, 2026. Chepke C, Durgam S, Earley W, et al. Metabolic Profile of Adjunctive Lumateperone 42 mg in Major Depressive Disorder: A Pooled Analysis of 2 Randomized, Placebo-Controlled Trials. Psych Congress 2026 Annual Meeting; Sept. 15-19, 2026. Chen H, Namjoshi M, Wu E, et al. Total Cost per Remitter of Lumateperone Versus Cariprazine for the Treatment of Major Depressive Disorder in the United States. Psych Congress 2026 Annual Meeting; Sept. 15-19, 2026. Liu Z, Namjoshi M, Obando C, et al. Real-World Lumateperone Dosing Patterns and Treatment Duration in Bipolar Depression. Psych Congress 2026 Annual Meeting; Sept. 15-19, 2026. Chepke C, Fu DJ, Himedan M, et al. Montgomery-Åsberg Depression Rating Scale Anhedonia Factor Score Following Esketamine Nasal Spray Monotherapy in Adult Patients With Treatment-Resistant Depression: A Post Hoc Analysis. Psych Congress 2026 Annual Meeting; Sept. 15-19, 2026. Cutler AJ, Drzayich J, Fu DJ, et al. Esketamine Nasal Spray on Anhedonia and Functional Outcomes: Findings from the Ventura Real-World Evidence Study. Psych Congress 2026 Annual Meeting; Sept. 15-19, 2026. Benson C, Doshi J, Geng Z, et al. Association of Schizophrenia-Related Hospitalization Before Long-Acting Injectable Antipsychotic Initiation and Outcomes Among Young Dual Eligibles. Psych Congress 2026 Annual Meeting; Sept. 15-19, 2026. Citrome L, Cline F, Han J, et al. Treatment Satisfaction, Quality of Life, Satisfaction with Participation in Social Roles, and Caregiver Burden In Adults with Schizophrenia Treated with Paliperidone Palmitate Long-Acting Injectables. Psych Congress 2026 Annual Meeting; Sept. 15-19, 2026. Cambron-Mellott J, Dwibedi N, Hamilton J, et al. Incidence of cardiometabolic events among adults with major depressive disorder with and without insomnia symptoms: a real-world evidence study. Psych Congress 2026 Annual Meeting; Sept. 15-19, 2026. Benson C, Campbell A, Johnston K, et al. Association of Insomnia Symptoms in Major Depressive Disorder with Healthcare Resource Use and Cardiovascular and Metabolic Conditions - Analysis of National Health & Nutrition Examination Survey. Psych Congress 2026 Annual Meeting; Sept. 15-19, 2026. Creel S, Hebert Z, Johnston K, et al. Understanding Insomnia Management in Major Depressive Disorder Through Patient-Provider Discourse. Psych Congress 2026 Annual Meeting; Sept. 15-19, 2026. World Health Organization. Bipolar disorder. September 2025. Accessed August 2026. https://www.who.int/news-room/fact-sheets/detail/bipolar-disorder   National Health Institute. Bipolar Disorder. Accessed August 2026. https://www.nimh.nih.gov/health/statistics/bipolar-disorder#part_2606 Oliva V, Fico G, De Prisco M et al. Bipolar disorders: an update on critical aspects. Lancet Reg Health Eur. 2024;48. doi:10.1016/j.lanepe.2024.101135. Cleveland Clinic. Mania. April 2026. Accessed August 2026. https://my.clevelandclinic.org/health/diseases/21603-mania World Health Organization. Mental disorders. Accessed May 2026. https://www.who.int/news-room/fact-sheets/detail/mental-disorders National Alliance on Mental Health. Mental health by the numbers. Accessed May 2026. https://www.nami.org/mental-health-by-the-numbers/   World Health Organization. Depressive disorder (depression). Accessed October 2025. who.int/news-room/fact-sheets/detail/depression Key substance use and mental health indicators in the United States: results from the 2023 national survey on drug use and health. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Published July 2024. Accessed May 2026. https://www.samhsa.gov/data/report/2023-nsduh-annual-national-report Su YA and Si T. Progress and challenges in research of the mechanisms of anhedonia in major depressive disorder. Gen Psychiatr. 2022;35:e100724. doi:10.1136/gpsych-2021-10072   Pandya M, et al. Where in the Brain Is Depression? Curr Psychiatry Rep. 2012;14:634–642. doi:10.1007/s11920-012-0322-7 Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov;163(11):1905-17. doi:10.1176/ajp.2006.163. Arnaud AM, Brister TS, Duckworth K, et al. Impact of major depressive disorder on comorbidities: a systematic literature review. J Clin Psychiatry. 2022;83(6):21r14328. Cao B, Zhu J, Zuckerman H, et al. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2019;92:109–117. doi: 10.1016/j.pnpbp.2019.01.002 Kale H, Ganz ML, Ghosh, R. Burden of prominent anhedonia in major depressive disorder reflected in polypharmacy, healthcare use and humanistic outcomes. Poster presentation at Psych Congress 2024, Boston, MA, United States. Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res. 2003;37(1):9-15. doi:10.1016/S0022-3956(02)00052-3 Taddei-Allen P. Economic Burden and Managed Care Considerations for the Treatment of Insomnia. AJMC. Updated April 12, 2020. Accessed May 2026. https://www.ajmc.com/view/economic-burden-and-managed-care-considerations-for-the-treatment-of-insomnia  Ağargün MY, Kara H, Solmaz M. Sleep disturbances and suicidal behavior in patients with major depression. J Clin Psychiatry. 1997;58(6):249-51 National Institute of Mental Health. Major Depression. Accessed May 2026. https://www.nimh.nih.gov/health/statistics/major-depression Zhdanava M, Pilon D, Ghelerter I, et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. 2021;82(2):20m13699. doi:10.4088/JCP.20m13699   Sanacora G, Zarate C, Krystal J, et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008;7(5):426-437. doi:10.1038/nrd2462 Treatment Advocacy Center. Schizophrenia Fact Sheet. Accessed May 2026. www.tac.org/reports_publications/schizophrenia-fact-sheet/. Tandon, Rajiv et al. "The schizophrenia syndrome, circa 2024: What we know and how that informs its nature." Schizophrenia research vol. 264 (2024): 1-28. doi:10.1016/j.schres.2023.11.015 Birchwood, M. "Early intervention and sustaining the management of vulnerability." The Australian and New Zealand Journal of Psychiatry vol. 34 Suppl (2000): S181-4. doi:10.1080/000486700241 National Alliance on Mental Illness. Understanding Schizophrenia. Accessed May 2026. https://www.nami.org/types-of-conditions/schizophrenia/ Alphs L, et al. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable therapy. Int Clin Psychopharmacol. 2016;31(4)202-209. doi:10.1097/YIC.0000000000000125 INVEGA SUSTENNA® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. INVEGA TRINZA® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. INVEGA HAFYERA® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. Recourt K, de Boer P, Zuiker R, et al. The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder [published correction appears in Transl Psychiatry. 2019 Oct 2;9(1):240. doi:10.1038/s41398-019-0585-4 Nollet M, Leman S. Role of orexin in the pathophysiology of depression: potential for pharmacological intervention. CNS Drugs. 2013;27(6):411-422. doi:10.1007/s40263-013-0064-z Brooks S, Jacobs GE, de Boer P, et al. The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia. J Psychopharmacol. 2019;33(2):202-209. doi:10.1177/0269881118822258 SOURCE Johnson & Johnson